Evoke Pharma Inc financial data

Symbol
EVOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
420 Stevens Avenue, Suite 230, Solana Beach, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 107 % -66.8%
Quick Ratio 5.76 % -43.4%
Debt-to-equity 1.36K % +421%
Return On Equity -964 % -273%
Return On Assets -66.1 % +7.72%
Operating Margin -82.6 % +61%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 735K shares -78%
Common Stock, Shares, Outstanding 735K shares -78%
Entity Public Float 5.3M USD
Common Stock, Value, Issued 73 USD -78.1%
Weighted Average Number of Shares Outstanding, Basic 1.36M shares +389%
Weighted Average Number of Shares Outstanding, Diluted 1.36M shares +389%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.53M USD +111%
Operating Income (Loss) -6.22M USD +17.8%
Nonoperating Income (Expense) -312K USD +14.7%
Net Income (Loss) Attributable to Parent -6.53M USD +17.7%
Earnings Per Share, Basic 3.95 USD/shares +86.1%
Earnings Per Share, Diluted 3.95 USD/shares +86.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.18M USD +31%
Accounts Receivable, after Allowance for Credit Loss, Current 1.23M USD
Inventory, Net 545K USD +6.05%
Other Assets, Current 27.7K USD +140%
Assets, Current 12.1M USD +36%
Operating Lease, Right-of-Use Asset 13.4K USD -91.3%
Assets 12.1M USD +35.2%
Employee-related Liabilities, Current 426K USD -30.5%
Liabilities, Current 9.47M USD +12.2%
Operating Lease, Liability, Noncurrent 13.4K USD
Liabilities 9.47M USD +12.2%
Retained Earnings (Accumulated Deficit) -126M USD -5.45%
Stockholders' Equity Attributable to Parent 2.66M USD +395%
Liabilities and Equity 12.1M USD +35.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.58M USD -58.2%
Net Cash Provided by (Used in) Financing Activities 7.54M USD
Common Stock, Shares Authorized 100M shares +100%
Common Stock, Shares, Issued 735K shares -78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.96M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.18M USD +31%
Deferred Tax Assets, Valuation Allowance 2.29M USD +9.97%
Deferred Tax Assets, Gross 2.29M USD +8.46%
Operating Lease, Liability, Current 13.4K USD -90.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 134K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 63K USD
Deferred Tax Assets, Operating Loss Carryforwards 25.8M USD +5.31%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 2M USD 0%
Operating Lease, Payments 146K USD +274%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 501K USD +0.27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%